Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 76,735	$ 53,245	$ 221,964	$ 140,121
Research and development related success payments and contingent consideration	(6,062)	16,753	(79,428)	67,778
General and administrative	15,514	13,433	48,240	37,731
Total operating expenses	86,187	83,431	190,776	245,630
Loss from operations	(86,187)	(83,431)	(190,776)	(245,630)
Interest income, net	1,173	158	2,149	409
Other income (expense), net	(106)	10	(406)	24
Net loss	$ (85,120)	$ (83,263)	$ (189,033)	$ (245,197)
Net income (loss) per common share - basic	$ (0.45)	$ (0.46)	$ (1.01)	$ (1.53)
Net income (loss) per common share - diluted	$ (0.45)	$ (0.46)	$ (1.01)	$ (1.53)
Weighted-average number of common shares - basic	189,303	181,827	187,645	160,515
Weighted-average number of common shares - diluted	189,303	181,827	187,645	160,515